Literature DB >> 24025520

The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters.

Brett Delahunt1, John C Cheville, Guido Martignoni, Peter A Humphrey, Cristina Magi-Galluzzi, Jesse McKenney, Lars Egevad, Ferran Algaba, Holger Moch, David J Grignon, Rodolfo Montironi, John R Srigley.   

Abstract

The International Society of Urological Pathology 2012 Consensus Conference made recommendations regarding classification, prognostic factors, staging, and immunohistochemical and molecular assessment of adult renal tumors. Issues relating to prognostic factors were coordinated by a workgroup who identified tumor morphotype, sarcomatoid/rhabdoid differentiation, tumor necrosis, grading, and microvascular invasion as potential prognostic parameters. There was consensus that the main morphotypes of renal cell carcinoma (RCC) were of prognostic significance, that subtyping of papillary RCC (types 1 and 2) provided additional prognostic information, and that clear cell tubulopapillary RCC was associated with a more favorable outcome. For tumors showing sarcomatoid or rhabdoid differentiation, there was consensus that a minimum proportion of tumor was not required for diagnostic purposes. It was also agreed upon that the underlying subtype of carcinoma should be reported. For sarcomatoid carcinoma, it was further agreed upon that if the underlying carcinoma subtype was absent the tumor should be classified as a grade 4 unclassified carcinoma with a sarcomatoid component. Tumor necrosis was considered to have prognostic significance, with assessment based on macroscopic and microscopic examination of the tumor. It was recommended that for clear cell RCC the amount of necrosis should be quantified. There was consensus that nucleolar prominence defined grades 1 to 3 of clear cell and papillary RCCs, whereas extreme nuclear pleomorphism or sarcomatoid and/or rhabdoid differentiation defined grade 4 tumors. It was agreed upon that chromophobe RCC should not be graded. There was consensus that microvascular invasion should not be included as a staging criterion for RCC.

Entities:  

Mesh:

Year:  2013        PMID: 24025520     DOI: 10.1097/PAS.0b013e318299f0fb

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  194 in total

1.  [Vancouver classification of renal tumors: Recommendations of the 2012 consensus conference of the International Society of Urological Pathology (ISUP)].

Authors:  G Kristiansen; B Delahunt; J R Srigley; C Lüders; J-M Lunkenheimer; H Gevensleben; T Thiesler; R Montironi; L Egevad
Journal:  Pathologe       Date:  2015-05       Impact factor: 1.011

Review 2.  Chinese guidelines on the management of renal cell carcinoma (2015 edition).

Authors:  Jun Guo; Jianhui Ma; Yan Sun; Shukui Qin; Dingwei Ye; Fangjian Zhou; Zhisong He; Xinan Sheng; Feng Bi; Dengfeng Cao; Yingxia Chen; Yiran Huang; Houjie Liang; Jun Liang; Jiwei Liu; Wenchao Liu; Yueyin Pan; Yongqian Shu; Xin Song; Weibo Wang; Xiuwen Wang; Xiaoan Wu; Xiaodong Xie; Xin Yao; Shiying Yu; Yanqiao Zhang; Aiping Zhou
Journal:  Ann Transl Med       Date:  2015-11

3.  [Kidney tumours].

Authors:  H Moch
Journal:  Pathologe       Date:  2016-03       Impact factor: 1.011

Review 4.  Epidemiology, biology and treatment of sarcomatoid RCC: current state of the art.

Authors:  Cedric Lebacle; Aydin Pooli; Thomas Bessede; Jacques Irani; Allan J Pantuck; Alexandra Drakaki
Journal:  World J Urol       Date:  2018-06-01       Impact factor: 4.226

5.  Reappraisal of Morphologic Differences Between Renal Medullary Carcinoma, Collecting Duct Carcinoma, and Fumarate Hydratase-deficient Renal Cell Carcinoma.

Authors:  Chisato Ohe; Steven C Smith; Deepika Sirohi; Mukul Divatia; Mariza de Peralta-Venturina; Gladell P Paner; Abbas Agaimy; Mitual B Amin; Pedram Argani; Ying-Bei Chen; Liang Cheng; Maurizio Colecchia; Eva Compérat; Isabela Werneck da Cunha; Jonathan I Epstein; Anthony J Gill; Ondřej Hes; Michelle S Hirsch; Wolfram Jochum; Lakshmi P Kunju; Fiona Maclean; Cristina Magi-Galluzzi; Jesse K McKenney; Rohit Mehra; Gabriella Nesi; Adeboye O Osunkoya; Maria M Picken; Priya Rao; Victor E Reuter; Paulo Guilherme de Oliveira Salles; Luciana Schultz; Satish K Tickoo; Scott A Tomlins; Kiril Trpkov; Mahul B Amin
Journal:  Am J Surg Pathol       Date:  2018-03       Impact factor: 6.394

6.  [The WHO/ISUP grading system for renal carcinoma].

Authors:  H Moch
Journal:  Pathologe       Date:  2016-07       Impact factor: 1.011

7.  Percentage of sarcomatoid component as a prognostic indicator for survival in renal cell carcinoma with sarcomatoid dedifferentiation.

Authors:  Mehrad Adibi; Arun Z Thomas; Leonardo D Borregales; Megan M Merrill; Rebecca S Slack; Hsiang-Chun Chen; Kanishka Sircar; Paari Murugan; Pheroze Tamboli; Eric Jonasch; Nizar M Tannir; Surena F Matin; Christopher G Wood; Jose A Karam
Journal:  Urol Oncol       Date:  2015-05-23       Impact factor: 3.498

8.  Tumor-infiltrating neutrophils predict therapeutic benefit of tyrosine kinase inhibitors in metastatic renal cell carcinoma.

Authors:  Jiajun Wang; Li Liu; Qi Bai; Chenzhang Ou; Ying Xiong; Yang Qu; Zewei Wang; Yu Xia; Jianming Guo; Jiejie Xu
Journal:  Oncoimmunology       Date:  2018-10-02       Impact factor: 8.110

9.  Grade 4 unclassified renal cell carcinoma with sarcomatoid component expressing S-100 protein. A case report with peculiar diagnostic and therapeutic implications.

Authors:  Gianmaria Miolo; Anthony Ash; Angela Buonadonna; Giovanni Lo Re; Elena Torrisi; Silvia Cervo; Davide Adriano Santeufemia; Alessandro Tuzi; Vincenzo Canzonieri
Journal:  Cancer Biol Ther       Date:  2014       Impact factor: 4.742

10.  The classification of pediatric and young adult renal cell carcinomas registered on the children's oncology group (COG) protocol AREN03B2 after focused genetic testing.

Authors:  Mariana M Cajaiba; Lisa M Dyer; James I Geller; Lawrence J Jennings; David George; Dawn Kirschmann; Stephen M Rohan; Nicholas G Cost; Geetika Khanna; Elizabeth A Mullen; Jeffrey S Dome; Conrad V Fernandez; Elizabeth J Perlman
Journal:  Cancer       Date:  2018-06-15       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.